Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biological standardization of Alternaria alternata allergen extract
2013-001308-13Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Jul 2013
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of alternaria alternata allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and allergic asthma, sponsored by LETI Pharma. Primary endpoint: Skin prick test wheal area. Started Jul 2013; status: completed.
02
Drugs
alternaria alternata allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)allergic asthma
Beyond the preview
Go deeper on 2013-001308-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001308-13.